Get notified when ZNTL files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: ZNTL Zentalis Pharmaceuticals, Inc. 8-K

Zentalis expands board to seven directors, appoints Shannon Campbell to Class I seat

Filed May 27, 2026 · Period ending May 22, 2026 · ~1 min read

Key Changes

  • medium

    Board expanded from six to seven members with appointment of Shannon Campbell as Class I director effective May 22, 2026, term runs through 2027 Annual Meeting.

  • medium

    Campbell granted 114,200 RSUs (0.16% of outstanding shares) on May 26, 2026, vesting in three equal annual installments, aligning director interests with shareholders.

  • low

    Campbell appointed to Compensation Committee, which oversees executive pay decisions, and will receive standard non-employee director compensation of $52,500 annually.

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.

Partner

Trade ZNTL commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · May 27, 2026 · How we verify